We were also pleased to see sequential growth in both business lines, with lymphedema revenue up 10% versus Q2 and airway clearance revenue, which is typically more seasonally depressed in Q3, up 3% versus Q2. Q3 gross margins increased 80 basis points year over year to 76%, while on the bottom line, adjusted EBITDA increased 34% year over year to $14.4 million. We also made progress with respect to our balance sheet in terms of strong cash generation. Based on our performance through the third quarter and ...